| obesity and overweight | versus placebo or control No demonstrated result for efficacy | 3 trials | meta-analysis | | | Trial | control | p<0.05 | harm | NS |
|---|
| Anderson, 2002 | Bupropion vs placebo | | | | | Croft, 2002 | Bupropion vs placebo | | | | | Jain, 2002 | Bupropion vs placebo | | | |
| Trial | Treatments | Patients | Method |
|---|
| Anderson, 2002 | bupropion SR 300, or 400 mg/d. (n=105) vs. placebo (n=112) | obese adults | double-blind Sample size: 105/112 Primary endpoint: FU duration: 24 weeks | | Croft, 2002 | Bupropion, 300 mg for 44 wk (n=210) vs. Placebo (n=213) | patients with major depression responder to open-label treatment with bupropion SR | double-blind Sample size: 210/213 Primary endpoint: FU duration: 44 weeks | | Jain, 2002 | bupropion SR 300 mg/d (n=213) vs. Placebo (n=209) | Obese adults (body mass index, 30 to 44 kg/m(2)) not currently meeting criteria for major depression but with depressive symptoms (Beck Depression Inventory score 10-30) | double-blind Sample size: 213/209 Primary endpoint: FU duration: 26 weeks |
|
